Sequana Medical Reports Positive data of DSR 2.0 in P-I/IIa (MOJAVE) study for Congestive Heart Failure (CHF)
Shots:
- The P-I/IIa (MOJAVE) study evaluates DSR 2.0 in diuretic-resistant CHF patients experiencing persistent congestion that began with a non-randomized cohort of 3 patients for 4 wks. & 3mos. safety follow-up and will proceed to a randomized cohort of up to 30 patients after DSMB approval planned in Q1’24
- In the non-randomized cohort, patients during DSR treatment maintained fluid balance without loop diuretics showed improved cardiorenal status. Diuretic response normalized (324% increase in urinary Na excretion), & kidney function improved (eGFR by 47%, blood urea nitrogen by 57%). NT-proBNP levels remained normal, indicating stable cardiovascular status
- Additionally Patient 1, 11.4wks. after the last DSR therapy, experienced a 97% reduction in the furosemide equivalent dose compared to baseline. Patient 2, at 6.4wks. achieved a complete 100% reduction, & Patient 3, at 1.4wks. demonstrated a 100% reduction
Ref: Sequana Medical | Image: Sequana Medical
Related News:- NTU SingaporeTTSH Develops AI based Smart Medical Device for Early Detection of Congestive Heart Failure
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
